Cytoreductive therapy In cases of advanced systemic mastocytosis or rare cases with indolent systemic mastocytosis with very troublesome symptoms, cytoreductive therapy can be indicated. ɑ-interferon. Given as subcutaneous injections. Side effects include fatigue and influenza-like symptoms Cladribine (CdA). Chemotherapy which is given as subcutaneous injections. Side effects include immunodeficiency and infections. Tyrosine kinase inhibitors (TKI) Midostaurin. TKI acting on many different tyrosine kinases, approved by FDA and EMA for advanced mastocytosis Imatinib. Can have effect in rare cases without mutation in KIT(D816V) Masitinib. Is being tested in trials. Not approved. Midostaurin - 60% respond. Avapritinib in trials; currently being tested but showing promise in reduction of tryptase levels.
Cytoreductive therapy In cases of advanced systemic mastocytosis or rare cases with indolent systemic mastocytosis with very troublesome symp.toms, cytoreductive therapy can be indicated. ɑ-interferon. Given as subcutaneous injections. Side effects include fatigue and influenza-like symptoms Cladribine (CdA). Chemotherapy which is given as subcutaneous injections. Side effects include immunodeficiency and infections. Tyrosine kinase inhibitors (TKI) Midostaurin. TKI acting on many different tyrosine kinases, approved by FDA and EMA for advanced mastocytosis Imatinib. Can have effect in rare cases without mutation in KIT(D816V) Masitinib. Is being tested in trials. Not approved Midostaurin - 60% respond. Avapritinib in trials; currently being tested but showing promise in reduction of tryptase levels.